Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients
- PMID: 11052270
- DOI: 10.1007/s001470050712
Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients
Abstract
Although acute rejection (AR) has been shown to correlate with decreased long-term renal allograft survival, we have noted AR in recipients who subsequently had stable function for more than 5 years. We reviewed 109 renal graft recipients with a minimum of 1 year graft survival and follow-up of 5-8 years. Post-transplant sodium iothalamate clearances (IoCI) measured at 3 months and yearly thereafter were used to separate recipients into 2 groups. In 61 patients (stable group), there was no significant decrease ( > 20 % reduction in IoCl over 2 consecutive years) in IoCl. Forty-eight patients had significant declines in IoCl (decline group). Groups were compared for incidence, severity, timing, and completeness of reversal of AR. Rejection was considered completely reversed if the post-AR serum creatinine (Scr) returned to or below the pre-AR nadir Scr after anti-rejection therapy. The incidence of AR was not significantly different between groups (47% vs 52%). A trend toward a lower mean number of AR episodes per patient was noted in the stable group (0.69 vs 1.04, P = 0.096), but the timing of AR was not different. Steroid-resistant AR occurred in approximately 25 % of both groups. A striking difference was seen in complete reversal of AR, with the stable group having 100% (42/42 episodes of AR in 29 patients) complete reversal whereas only 32 % (8/25) of the patients in the decline group had complete reversal (P < < 0.001). Of 8 declining patients with complete reversal, graft loss was due to chronic rejection (CR) in only 3. Seventeen declining patients had incomplete reversal of AR, and 82 % (14/17) lost their grafts to CR. Overall, only 8% (3/37) of the recipients with complete reversal of AR developed CR. No patients with incompletely reversed AR had stable long-term function as measured by IoCl. AR is not invariably deleterious to long-term renal graft function if each episode of AR can be completely reversed.
Similar articles
-
Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.Transplantation. 1997 Mar 27;63(6):845-8. doi: 10.1097/00007890-199703270-00009. Transplantation. 1997. PMID: 9089224
-
Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.Am J Nephrol. 1999;19(6):634-40. doi: 10.1159/000013534. Am J Nephrol. 1999. PMID: 10592356
-
Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.Transplantation. 2001 Apr 27;71(8):1091-7. doi: 10.1097/00007890-200104270-00014. Transplantation. 2001. PMID: 11374408 Clinical Trial.
-
The impact of late acute rejection after cadaveric kidney transplantation.Clin Transplant. 2001 Aug;15(4):221-7. doi: 10.1034/j.1399-0012.2001.150401.x. Clin Transplant. 2001. PMID: 11683814 Review.
-
Impact of acute rejection on development of chronic rejection in pediatric renal transplant recipients.Pediatr Transplant. 2000 May;4(2):92-9. doi: 10.1034/j.1399-3046.2000.00096.x. Pediatr Transplant. 2000. PMID: 11272615 Review.
Cited by
-
Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study.Am J Transplant. 2010 Feb;10(2):324-30. doi: 10.1111/j.1600-6143.2009.02954.x. Epub 2010 Jan 5. Am J Transplant. 2010. PMID: 20055809 Free PMC article.
-
Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.Cochrane Database Syst Rev. 2017 Jul 20;7(7):CD004756. doi: 10.1002/14651858.CD004756.pub4. Cochrane Database Syst Rev. 2017. PMID: 28731207 Free PMC article.
-
Donor-Derived Cell-Free DNA (dd-cfDNA) in Kidney Transplant Recipients With Indication Biopsy-Results of a Prospective Single-Center Trial.Transpl Int. 2023 Nov 3;36:11899. doi: 10.3389/ti.2023.11899. eCollection 2023. Transpl Int. 2023. PMID: 38020751 Free PMC article. Clinical Trial.
-
Capillary deposition of complement C4d and C3d in Chinese renal allograft biopsies.Dis Markers. 2015;2015:397613. doi: 10.1155/2015/397613. Epub 2015 Mar 4. Dis Markers. 2015. PMID: 25821339 Free PMC article.
-
Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies.Drugs. 2019 Dec;79(18):1947-1962. doi: 10.1007/s40265-019-01217-7. Drugs. 2019. PMID: 31713065 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials